- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Adisyn
Mawson Finland Limited
Purpose Bitcoin ETF
Pinnacle Silver and Gold
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Raza Bokhari, Executive Co-Chairman of the Board and CEO talks about the company’s strategic stock consolidation with James West of Midas Letter.
Raza Bokhari, Executive Co-Chairman of the Board and CEO of FSD Pharma (CSE:HUGE) was featured in a sponsored interview published by Midas Letter. In the interview, Raza talks about the strategic stock consolidation that host James West says, “seems to have been done with a specific objective in mind.” Raza says the company presents, “a huge opportunity for us and our shareholders in this eco system that is groundbreaking.”
Raza also cited the need for uplisting and stock consolidation to attract “institutional-grade investment.”
FSD Pharma announced a share consolidation on October 11, 2019. According to the press release:
Effective October 16, 2019, with a record date of October 17, 2019, the Company expects to begin trading the Class B Shares on the Canadian Securities Exchange on a post-Consolidation basis under its existing name and ticker symbol. The new CUSIP and ISIN for the Class B Shares are 35954B206 and CA35954B2066, respectively.
The Company currently has 1,582,966,252 Class B Shares outstanding and the Consolidation will reduce the issued and outstanding Class B Shares to approximately 7,874,809 Class B Shares. The Consolidation was approved by FSD shareholders at the Company’s special meeting held on January 22, 2019, and will allow the Company to continue to pursue the listing of the Class B Shares on a major U.S. exchange.
Click here to connect with FSD Pharma Inc, (CSE:HUGE) for an Investor Presentation.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.